Quick Answer
Matinas BioPharma Holdings, Inc. reported Total Revenue of $1.10 million for the year ending 2023.
- Matinas BioPharma Holdings, Inc. showed a decrease of -65.6% in Total Revenue from 2022 to 2023.
- This data is from Matinas BioPharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2014 to 2023 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $0.00 | Q1 2015: $57.6 thousand | Q2 2015: $77.0 thousand | Q3 2015: $59.9 thousand | Q1 2016: $0.00 | Q2 2016: $0.00 | Q3 2016: $0.00 | Q1 2017: $15.0 thousand | Q2 2017: $44.9 thousand | Q3 2017: $44.9 thousand | Q1 2018: $29.9 thousand | Q2 2018: $89.8 thousand | Q2 2019: $89.8 thousand | Q2 2019: $89.8 thousand | Q3 2020: $95.8 thousand | Q1 2021: $33.3 thousand | Q2 2022: $1.06 million | Q3 2022: $1.06 million | Q1 2023: $1.10 million.
- Historical annual values: Fiscal year 2023: $1.10 million | Fiscal year 2022: $3.19 million | Fiscal year 2021: $33.0 thousand | Fiscal year 2020: $158.3 thousand | Fiscal year 2019: $89.8 thousand | Fiscal year 2018: $119.8 thousand | Fiscal year 2018: $119.8 thousand | Fiscal year 2017: $149.7 thousand | Fiscal year 2016: $0.00 | Fiscal year 2015: $194.5 thousand | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: